Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
13.87
+0.61 (4.60%)
At close: May 4, 2026, 4:00 PM EDT
13.88
+0.01 (0.07%)
After-hours: May 4, 2026, 7:58 PM EDT
Intellia Therapeutics Revenue
In the year 2025, Intellia Therapeutics had annual revenue of $67.67M with 16.92% growth. Intellia Therapeutics had revenue of $23.02M in the quarter ending December 31, 2025, with 78.79% growth.
Revenue (ttm)
$67.67M
Revenue Growth
+16.92%
P/S Ratio
24.21
Revenue / Employee
$179,499
Employees
377
Market Cap
1.64B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 67.67M | 9.79M | 16.92% |
| Dec 31, 2024 | 57.88M | 21.60M | 59.55% |
| Dec 31, 2023 | 36.28M | -15.85M | -30.40% |
| Dec 31, 2022 | 52.12M | 19.07M | 57.69% |
| Dec 31, 2021 | 33.05M | -24.94M | -43.01% |
| Dec 31, 2020 | 57.99M | 14.89M | 34.55% |
| Dec 31, 2019 | 43.10M | 12.67M | 41.63% |
| Dec 31, 2018 | 30.43M | 4.32M | 16.53% |
| Dec 31, 2017 | 26.12M | 9.64M | 58.49% |
| Dec 31, 2016 | 16.48M | 10.44M | 172.65% |
| Dec 31, 2015 | 6.04M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Innoviva | 411.33M |
| Iovance Biotherapeutics | 263.50M |
| Monte Rosa Therapeutics | 123.67M |
| Vir Biotechnology | 68.56M |
| Agios Pharmaceuticals | 66.05M |
| Nuvation Bio | 62.90M |
| Nanobiotix | 38.27M |
| AtaiBeckley | 4.09M |
NTLA News
- 3 days ago - Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 days ago - Intellia Therapeutics Announces Pricing of Public Offering of Common Stock - GlobeNewsWire
- 7 days ago - Intellia Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 7 days ago - Intellia Therapeutics FDA Rolling Application For Gene Therapy Puts Hype To Test - Benzinga
- 7 days ago - Intellia Therapeutics Transcript: Study result - Transcripts
- 7 days ago - Intellia Therapeutics' rare genetic disorder therapy meets main goal in trial - Reuters
- 7 days ago - Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial - CNBC
- 7 days ago - Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema - GlobeNewsWire